Drugs Made In America Acquisition net income falls 24.55% to $1.73 million in Q2 FY26

• Drugs Made In America Acquisition posted net income of $1.73 million for the quarter ended June 30, 2026, down 24.55% year over year.
• Interest income from the trust account fell 23.00% to $1.86 million.
• General and administrative costs rose 3.80% to $136,934.
• Signed a definitive merger agreement with Power Analytics Global Corporation on April 29, 2026; deal targets a Nasdaq listing post-close.
• Shareholder redemptions withdrew $99.31 million from the trust account; BV Advisory Partners deposited $600,000 for extensions through June 30.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Drugs Made In America Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-090035), on August 14, 2026, and is solely responsible for the information contained therein.